Physician

Jaymeson Scott Stroud, M.D.

According to 2025 Medicare claims, Jaymeson Stroud, M.D. (NPI: 1619094513) practices radiation oncology in the Jacksonville, FL market, with the plurality of this provider's patient population coming from Duval, FL. This provider's primary affiliated billing organization is ACKERMAN CANCER CENTER, PA (NPI: 1972529493; TIN: 59-2037695) and primary practice location at 32223-6612. Stroud is affiliated with the Caravan Health ACO 50 LLC (ACO ID: A5160), participating under the MSSP model.

Stroud's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 615 traditional Medicare patients, billed 9,044 HCPCS/CPT codes, and received $2,158,166 in Medicare payments. The top billing code was 77290 (Obtaining data needed to develop the optimal radiation treatment, 3 or more treatment areas or any number of treatment areas where special treatment is involved). Part D data shows 621 prescription claims across 186 beneficiaries totaling $56,985 in drug costs, led by Hydrocodone-Acetaminophen (Hydrocodone/Acetaminophen). Open Payments data shows 7 records totaling $511. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $173,971 to $2,158,166. Similarly, Part D prescription costs have risen steadily, from $1,729 to $56,985. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	244	2,495	$173,971
2016	202	1,998	$135,292
2017	82	1,110	$79,258
2018	89	1,688	$116,852
2019	101	1,501	$108,629
2020	121	1,651	$123,234
2021	169	1,610	$326,208
2022	390	5,196	$1,219,084
2023	539	9,018	$2,099,490
2024	615	9,044	$2,158,166

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	42	85	$1,729
2016	27	47	$677
2017	28	64	$1,350
2018	37	73	$1,162
2019	34	77	$834
2020	45	104	$1,499
2021	82	179	$3,076
2022	134	395	$6,963
2023	176	550	$9,247
2024	186	621	$56,985

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
77290	Obtaining data needed to develop the optimal radiation treatment, 3 or more treatment areas or any number of treatment areas where special treatment is involved	117	160	$337
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	111	148	$97
77014	Ct guidance for insertion of radiation therapy fields	112	1,018	$91
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	235	322	$64
G6002	Stereoscopic x-ray guidance for localization of target volume for the delivery of radiation therapy	142	1,599	$57

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	102	621	$1,820
Abiraterone Acetate	Abiraterone Acetate	11	360	$1,799
Fentanyl	Fentanyl	13	366	$1,136
Oxybutynin Chloride Er	Oxybutynin Chloride	19	1,410	$775
Tamsulosin Hcl	Tamsulosin Hcl	77	5,195	$759

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	7	$511	C. R. Bard, Inc. & Subsidiaries
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jaymeson Scott Stroud, M.D.?

Tedicare shows public-source Medicare data for Jaymeson Scott Stroud, M.D. (NPI 1619094513), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jaymeson Scott Stroud, M.D. have ACO affiliation data?

Jaymeson Scott Stroud, M.D. is shown with ACO affiliation data for Caravan Health ACO 50 LLC (MSSP, ACO ID A5160).

What billing organization is linked to Jaymeson Scott Stroud, M.D.?

Jaymeson Scott Stroud, M.D. is linked to ACKERMAN CANCER CENTER, PA (billing NPI 1972529493) in the available physician profile data.

Does Jaymeson Scott Stroud, M.D. have Open Payments data?

Jaymeson Scott Stroud, M.D. has 7 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.